Withaferin A Inhibits Helicobacter pylori-induced Production of IL-1β in Dendritic Cells by Regulating NF-κB and NLRP3 Inflammasome Activation
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Helicobacter pylori infection is associated with chronic gastritis, peptic ulcer, and gastric cancer. There is evidence that IL-1β is associated with the development of gastric cancer. Therefore, downregulation of H. pylori-mediated IL-1β production may be a way to prevent gastric cancer. Withaferin A (WA), a withanolide purified from Withania somnifera, is known to exert anti-inflammatory and anti- tumor effects. In the present study, we explored the inhibitory activity of WA on H. pylori-induced production of IL-1β in murine bone marrow-derived dendritic cells (BMDCs) and the underlying cellular mechanism. Cotreatment with WA decreased IL-1β production by H. pylori in BMDCs in a dose-dependent manner. H. pylori-induced gene expression of IL-1β and NLRP3 (NOD-like receptor family, pyrin domain containing 3) were also suppressed by WA treatment. Moreover, IκB-α phosphorylation by H. pylori infection was suppressed by WA in BMDCs. Western blot analysis revealed that H. pylori induced cleavage of caspase-1 and IL-1β, as well as increased procaspase-1 and pro IL-1β protein levels, and that both were suppressed by co-treatment with WA. Finally, we determined whether WA can directly inhibit activation of the NLRP3 inflammasome. NLRP3 activators induced IL-1β secretion in LPS-primed macrophages, which was inhibited by WA in a dose-dependent manner, whereas IL-6 production was not affected by WA. Moreover, cleavage of IL-1β and caspase-1 by NLRP3 activators was also dose-dependently inhibited by WA. These findings suggest that WA can inhibit IL-1β production by H. pylori in dendritic cells and can be used as a new preventive and therapeutic agent for gastric cancer.
Abstract
Helicobacter pylori infection is associated with chronic gastritis, peptic ulcer, and gastric cancer. There is evidence that IL-1β is associated with the development of gastric cancer. Therefore, downregulation of H. pylori-mediated IL-1β production may be a way to prevent gastric cancer. Withaferin A (WA), a withanolide purified from Withania somnifera, is known to exert anti-inflammatory and anti- tumor effects. In the present study, we explored the inhibitory activity of WA on H. pylori-induced production of IL-1β in murine bone marrow-derived dendritic cells (BMDCs) and the underlying cellular mechanism. Cotreatment with WA decreased IL-1β production by H. pylori in BMDCs in a dose-dependent manner. H. pylori-induced gene expression of IL-1β and NLRP3 (NOD-like receptor family, pyrin domain containing 3) were also suppressed by WA treatment. Moreover, IκB-α phosphorylation by H. pylori infection was suppressed by WA in BMDCs. Western blot analysis revealed that H. pylori induced cleavage of caspase-1 and IL-1β, as well as increased procaspase-1 and pro IL-1β protein levels, and that both were suppressed by co-treatment with WA. Finally, we determined whether WA can directly inhibit activation of the NLRP3 inflammasome. NLRP3 activators induced IL-1β secretion in LPS-primed macrophages, which was inhibited by WA in a dose-dependent manner, whereas IL-6 production was not affected by WA. Moreover, cleavage of IL-1β and caspase-1 by NLRP3 activators was also dose-dependently inhibited by WA. These findings suggest that WA can inhibit IL-1β production by H. pylori in dendritic cells and can be used as a new preventive and therapeutic agent for gastric cancer.
참고문헌 (66)
- Palese P, "Orthomyxoviridae: the viruses their replication.: Fields virology" (2007), Williams Wilkins
- Tong, S., "New world bats harbor diverse influenza A viruses", PLoS Pathog, 9, pp.e1003657~ (2013)
- Chizhmakov, I. V., "Selective proton permeability pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells", J. Physiol, 494, pp.329~336 (1996)
- Pinto, L. H., "Influenza virus M2 protein has ion channel activity", Cell, 69, pp.517~528 (1992)
- Long, J. X., "Cloning of full-length genes of H5N1 subtype Avian influenza virus strain A", duck, 093, pp.2004 analysis of the sequences, Wei Sheng Wu Xue. Bao[DOI]
- Ito, T., "Evolutionary analysis of the influenza A virus M gene with comparison of the M1 M2 proteins", J. Virol, 65, pp.5491~5498 (1991)
- Zebedee, S. L., "Nucleotide sequences of influenza A virus RNA segment 7: a comparison of five isolates", Nucleic Acids Res, 17, pp.2870~ (1989)
- Fiers, W., "A "universal" human influenza A vaccine", Virus Res, 103, pp.173~176 (2004)
- Kim, M. C., "Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus", Mol. Ther, 21, pp.485~492 (2013)
- Kim, M. C., "Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader stronger M2 immunity than live influenza A virus infection", Antiviral Res, 99, pp.328~335 (2013)
- De, F. M., "The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection", Vaccine, 24, pp.544~551 (2006)
- Fan, J., "Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, rhesus monkeys", Vaccine, 22, pp.2993~3003 (2004)
- Neirynck, S., "A universal influenza A vaccine based on the extracellular domain of the M2 protein", Nat. Med, 5, pp.1157~1163 (1999)
- Ionescu, R. M., "Pharmaceutical immunological evaluation of human papillomavirus viruslike particle as an antigen carrier", J. Pharm. Sci, 95, pp.70~79 (2006)
- Bessa, J., "Efficient induction of mucosal systemic immune responses by virus-like particles administered intranasally:implications for vaccine design", Eur. J. Immunol, 38, pp.114~126 (2008)
- Tompkins, S. M., "Matrix protein 2 vaccination protection against influenza viruses, including subtype H5N1", Emerg. Infect. Dis, 13, pp.426~435 (2007)
- Fu, T. M., "Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice monkeys", Vaccine, 27, pp.1440~1447 (2009)
- Ernst, W. A., "Protection against H1, H5, H6 H9 influenza A infection with liposomal matrix 2 epitope vaccines", Vaccine, 24, pp.5158~5168 (2006)
- Eliasson, D. G., "CTA1-M2e-DD : a novel mucosal adjuvant targeted influenza vaccine", Vaccine, 26, pp.1243~1252 (2008)
- Huleatt, J. W., "Potent immunogenicity efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligflagellin", Vaccine, 26, pp.201~214 (2008)
- Wu, F., "The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine", Vaccine, 27, pp.4320~4324 (2009)
- Kim, M. C., "Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity", Vaccine, 32, pp.5824~5831 (2014)
- De, F. M., "An influenza A vaccine based on tetrameric ectodomain of matrix protein 2", J. Biol. Chem, 283, pp.11382~11387 (2008)
- Liu, W., "High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity", Vaccine, 23, pp.366~371 (2004)
- Heinen, P. P., "Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus", J. Gen. Virol, 83, pp.1851~1859 (2002)
- Andersson, A. M., "Increased immunogenicity protective efficacy of influenza M2e fused to a tetramerizing protein", PLoS One, 7, pp.e46395~ (2012)
- Hessel, A., "MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 H7N1 viruses", PLoS One, 9, pp.e88340~ (2014)
- Zebedee, S. L., "Characterization of the influenza virus M2 integral membrane protein expression at the infected-cell surface from cloned cDNA", J. Virol, 56, pp.502~511 (1985)
- Song, J. M., "Vaccination inducing broad improved cross protection against multiple subtypes of influenza A virus", Proc. Natl. Acad. Sci. U.S.A, 108, pp.757~761 (2011)
- Kim, M. C., "Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity provides long-term cross protection", Mol. Ther, 22, pp.1364~1374 (2014)
- Harris, A., "Influenza virus pleiomorphy characterized by cryoelectron tomography", Proc. Natl. Acad. Sci. U.S.A, 103, pp.19123~19127 (2006)
- Zebedee, S. L., "Influenza A virus M2 protein:monoclonal antibody restriction of virus growth detection of M2 in virions", J. Virol, 62, pp.2762~2772 (1988)
- Treanor, J. J., "Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice", J. Virol, 64, pp.1375~1377 (1990)
- Song, J. M., "Influenza virus-like particles containing M2 induce broadly cross protective immunity", PLoS One, 6, pp.e14538~ (2011)
- Jegerlehner, A., "Influenza A vaccine based on the extracellular domain of M2:weak protection mediated via antibody-dependent NK cell activity", J. Immunol, 172, pp.5598~5605 (2004)
- Mozdzanowska, K., "Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 neuraminidase reduces the pulmonary virus titer but fails to clear the infection", Virology, 254, pp.138~146 (1999)
- Wang, B. Z., "Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles", J. Virol, 81, pp.10869~10878 (2007)
- Ada, G. L., "The immune response to influenza infection", Curr. Top. Microbiol. Immunol, 128, pp.1~54 (1986)
- Couch, R. B., "Immunity to influenza in man", Annu. Rev. Microbiol, 37, pp.529~549 (1983)
- Lamm, M. E., "Interaction of antigens antibodies at mucosal surfaces", Annu. Rev. Microbiol, 51, pp.311~340 (1997)
- Taylor, P. M., "Control of immune interferon release by cytotoxic T-cell clones specific for influenza", Immunology, 54, pp.607~614 (1985)
- Virelizier, J. L., "Immune responses to influenza virus in the mouse, their role in control of the infection", Br. Med. Bull, 35, pp.65~68 (1979)
- Bachmann, M. F., "Dendritic cells process exogenous viral proteins virus-like particles for class I presentation to CD8＋ cytotoxic T lymphocytes", Eur. J. Immunol, 26, pp.2595~2600 (1996)
- Huber, V. C., "Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections", J. Immunol, 166, pp.7381~7388 (2001)
- Hashimoto, Y., "Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils macrophages in mice", J. Immunol, 178, pp.2448~2457 (2007)
- Zharikova, D., "Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2", J. Virol, 79, pp.6644~6654 (2005)
- El, B. K., "Universal vaccine based on ectodomain of matrix protein 2 of influenza A:Fc receptors alveolar macrophages mediate protection", J. Immunol, 186, pp.1022~1031 (2011)
- Lee, Y. N., "Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination", Immunology, 143, pp.300~309 (2014)
- Fu, T. M., "Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus", Virology, 385, pp.218~226 (2009)
- Subbarao, K., "Scientific barriers to developing vaccines against avian influenza viruses", Nat. Rev. Immunol, 7, pp.267~278 (2007)
- Simhadri, V. R., "A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Cytokine Secretion by Resting Cytokine-Preactivated Natural Killer (NK) Cells", PLoS One, 10, pp.e0124677~ (2015)
- Anders, E. M., "Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin", J. Gen. Virol, 75, pp.615~622 (1994)
- Hirsch, R. L., "The role of complement in viral infections. III. Activation of the classical alternative complement pathways by Sindbis virus", J. Immunol, 124, pp.2507~2510 (1980)
- Cooper, N. R., "Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway", J. Exp. Med, 144, pp.970~984 (1976)
- Beebe, D. P., "Neutralization of influenza virus by normal human sera: mechanisms involving antibody complement", J. Immunol, 130, pp.1317~1322 (1983)
- Wang, R., "Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein", Antiviral Res, 80 (2008)
- Gerhard, W., "Role of the B-cell response in recovery of mice from primary influenza virus infection", Immunol. Rev, 159, pp.95~103 (1997)
- Heusser, C. H., "Receptors for IgG: subclass specificity of receptors on different mouse cell types the definition of two distinct receptors on a macrophage cell line", J. Exp. Med, 145, pp.1316~1327 (1977)
- Neuberger, M. S., "Activation of mouse complement by monoclonal mouse antibodies", Eur. J. Immunol, 11, pp.1012~1016 (1981)
- Doherty, P. C., "Effector CD4＋ CD8＋T-cell mechanisms in the control of respiratory virus infections", Immunol. Rev, 159, pp.105~117 (1997)
- Heidema, J., "Dynamics of human respiratory virus-specific CD8＋ T cell responses in blood airways during episodes of common cold", J. Immunol, 181, pp.5551~5559 (2008)
- McElhaney, J. E., "T cell responses are better correlates of vaccine protection in the elderly", J. Immunol, 176, pp.6333~6339 (2006)
- Bender, B. S., "Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance increased mortality after influenza virus challenge", J. Exp. Med, 175, pp.1143~1145 (1992)
- Jameson, J., "Human cytotoxic T-lymphocyte repertoire to influenza A viruses", J. Virol, 72, pp.8682~8689 (1998)
- Gianfrani, C., "Human memory CTL response specific for influenza A virus is broad multispecific", Hum. Immunol, 61, pp.438~452 (2000)
- Mozdzanowska, K., "Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2", Vaccine, 21, pp.2616~2626 (2003)